FDA Hikes Outsourcing Drug Facility Fees—Small Biz Pays $7,142
Published Date: 7/30/2026
Notice
Summary
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 rates for the establishment and reinspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a reinspection fee for each reinspection of an outsourcing facility. This document establishes the FY 2027 rates for the small business establishment fee ($7,142), the non-small business establishment fee ($22,074), and the reinspection fee ($21,427) for outsourcing facilities; provides information on how the fees for FY 2027 were determined; and describes the payment procedures outsourcing facilities should follow.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
FY2027 Outsourcing Facility Fees
If you operate an outsourcing facility that compounds human drugs and register with FDA, the FY 2027 annual establishment fee is $7,142 for qualified small businesses and $22,074 for non-small businesses. The FY 2027 reinspection fee is $21,427. These rates are effective October 1, 2026 through September 30, 2027.
Small Business Fee Exception Deadline
To qualify for the FY 2027 small business reduced establishment fee, entities had to submit their small business exception requests by April 30, 2026; that time has passed for FY 2027. Entities that wish to request a small business exception for FY 2028 should consult section 744K(c)(4) of the FD&C Act and FDA guidance.
Registration And Payment Deadlines
Outsourcing facilities must register between October 1, 2026 and December 31, 2026 to maintain status for FY2027 and should submit registration information by December 10, 2026 to allow time for invoicing and payment. Once FDA issues an invoice, you must pay the full invoiced amount within 15 calendar days or FDA will treat the registration submission as withdrawn; failure to register and complete payment by December 31, 2026 will result in loss of outsourcing facility status on January 1, 2027.
Payment Methods, Limits, And Collections
Payments to FDA must be in U.S. currency drawn on a U.S. bank and can be made online via Pay.gov using ACH (eCheck) or credit card; credit card payment is available only for balances under $25,000, and balances over $25,000 must use ACH. Reinspection fee invoices must be paid within 30 days, and unpaid reinspection fees will be treated as a government claim and referred to collections.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18529, Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking
The FDA wants your thoughts on how they collect info to track medical devices. This affects companies that make or handle these devices and aims to keep things safe and clear. You’ve got until November 10, 2026, to share your comments—no cost, just your voice!
2026-18612, Medical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Software
The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18551, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate
The Food and Drug Administration (FDA or Agency) is announcing the availability on its website of the final administrative order (final order) (OTC000008-1) titled "Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate." This final order amends "Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use" (Over- the-Counter (OTC) Monograph M020) to remove PABA and trolamine salicylate as sunscreen active ingredients. A sunscreen drug product containing PABA or trolamine salicylate is not generally recognized as safe and effective (GRASE).
Previous / Next Documents
Previous: 2026-15341, Animal Generic Drug User Fee Program Rates and Payment Procedures for Fiscal Year 2027
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2027 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs (JINADs), and for certain submissions related to JINAD files. This notice establishes the fee rates for FY 2027.
Next: 2026-15343, Generic Drug User Fee Rates for Fiscal Year 2027
The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2027 rates for GDUFA III fees.